Raymond James Raises Earnings Estimates for Profound Medical

Profound Medical Corp. (TSE:PRN) – Equities research analysts at Raymond James boosted their FY2024 EPS estimates for Profound Medical in a research report issued to clients and investors on Tuesday, February 18th. Raymond James analyst M. Freeman now forecasts that the company will post earnings of ($1.68) per share for the year, up from their prior estimate of ($1.79). Raymond James currently has a “Strong-Buy” rating on the stock. The consensus estimate for Profound Medical’s current full-year earnings is ($1.90) per share. Raymond James also issued estimates for Profound Medical’s Q4 2024 earnings at ($0.37) EPS, Q1 2025 earnings at ($0.37) EPS, Q2 2025 earnings at ($0.37) EPS, Q3 2025 earnings at ($0.37) EPS, Q4 2025 earnings at ($0.37) EPS, FY2025 earnings at ($1.48) EPS, FY2026 earnings at ($1.12) EPS, FY2027 earnings at ($0.24) EPS and FY2028 earnings at $1.62 EPS.

Profound Medical Price Performance

Shares of Profound Medical stock opened at C$10.09 on Thursday. The company has a quick ratio of 14.98, a current ratio of 6.12 and a debt-to-equity ratio of 20.05. The stock has a market capitalization of C$212.62 million, a price-to-earnings ratio of -5.24 and a beta of 0.81. Profound Medical has a twelve month low of C$7.90 and a twelve month high of C$15.75. The company has a 50-day simple moving average of C$10.04 and a two-hundred day simple moving average of C$10.89.

Insider Transactions at Profound Medical

In related news, Director Arun Menawat Dr. purchased 20,000 shares of the company’s stock in a transaction that occurred on Tuesday, December 10th. The stock was acquired at an average price of C$10.65 per share, with a total value of C$213,000.00. Also, Senior Officer Thomas Michael Tamberrino acquired 13,333 shares of the business’s stock in a transaction that occurred on Tuesday, December 10th. The shares were purchased at an average cost of C$10.65 per share, with a total value of C$141,996.45. Insiders own 8.62% of the company’s stock.

About Profound Medical

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.